Performance. Defined.

InVitria Blog | Cell Culture and Biotech Manufacturing Insights

InVitria: Solving the Vaccine Supply Challenge

Posted By Jeanne McAdara Ph.D. on 9/2/20 8:23 AM

Right now is an exciting time for vaccine science, with an unprecedented level of attention, resources, and testing being directed at the effort to control the COVID-19 pandemic. In this post, we share a new video and provide additional information to explain the role that InVitria’s recombinant human protein products play in accelerating the vaccine development timeline.

Read More

SARS-CoV2 and Influenza: A Double Threat

Posted By Jeanne McAdara Ph.D. on 7/28/20 9:00 AM

While we fight SARS-CoV-2, we must not turn our back on influenza

As of this writing, the SARS-CoV-2 virus has infected at least 15.5 million people worldwide and resulted in at least 632,000 deaths. While extreme public health measures such as testing, contact tracing, school closures, travel restrictions, stay-at-home orders, social distancing, and compulsory masking, appear to have tamed the spread of the virus in some parts of the world, the pandemic is still growing in a number of highly populated countries including the US and Brazil, and outbreaks are frequent everywhere as countries try to balance the risks of the virus against the very real risks of economic and mental health collapse.

Accordingly, a huge global effort is under way to develop vaccines that will provide widespread immunity against the virus, relieve the burden of COVID-19 morbidity and mortality, and allow communities to return to more sustainable social and economic behaviors.

In the US, a cooperative partnership between the CDC, the FDA, the NIH, BARDA, the DoD, private industry, and other federal agencies—known as Operation Warp Speed (OWS) -- is coordinating a massive effort to develop, test, approve, and deliver a safe and effective vaccine to US citizens by early 2021. Although that is an incredibly aggressive timeline for vaccine development, several candidates have shown promise in early testing and are poised to move into pivotal trials. No matter how long the effort takes, the research being done is sure to advance vaccine science in a paradigm-shifting way.

Read More

Recombinant Virus Platforms are Out in Front in the Race to Develop Vaccines Against SARS-CoV-2 and COVID-19 Disease

Posted By Jeanne McAdara Ph.D. on 6/12/20 8:00 AM

SARS-CoV-2 continues to circulate the globe, causing widespread illness, loss of life , and far-reaching societal and economic disruption. Public health measures like stay-at-home and safer-at-home have been successful in checking the virus’s geometric growth curve, and treatments are in development. However, epidemiologists generally agree that achieving “herd immunity” through a safe and effective vaccine is indispensable to overcoming this challenge to humanity’s social, mental, and economic health and wellbeing.

Read More

Expansion of Adherent HEK293t Cells in Flasks in Chemically Defined Cell Culture Media

Posted By Attie Pennybaker on 11/18/19 4:34 PM

Workflow Summary:

New call-to-actionCombine supplements of OptiPEAK HEK293t media. Generate stock solutions and prepare reagents. Adapt HEK293t cells in log phase growth from serum to OptiPEAK HEK293t chemically defined, serum free media. Subculture HEK293t cells every 2-3 days in T-75 flasks, calculating doubling time and population doublings to determine cumulative expansion results.

Read More

Stabilizing Virus with Albumin to Improve Yield

Posted By Randy Alfano Ph.D. on 10/22/19 11:02 AM

Workflow Summary:

Expand virus-producing cells to desired confluency. RemoveNew call-to-action growth medium and add the desired virus to be expanded (virus or plasmid DNA). Add Exbumin (Product Number: 777HSA097S) to the expression media and allow virus to propagate. Harvest culture and determine virus titer by preferred method.

Here, a general protocol is described for the addition of recombinant albumin, in the form of the product Exbumin, to virus production systems to stabilize infectious particles and thereby maximize viral yield.

 

Read More